Genmab — Maj 2020
-
Vel som forventet.
-
Genmab går fri af coronakrise: Øger omsætningen med 51 pct
Biotekselskabet Genmab har i første kvartal sneget sig rundt om coronakrisen og øget selskabets omsætning. Det fremgår af Genmabs regnskab, der er blevet offentliggjort onsdag. Salget endte i årets tr
borsen.dk (borsen.dk)
-
@Sukkeralf
January: First Clinical Trial Applications (CTAs) submitted for DuoBody-CD3x5T4 in Europe. -
Operating expenses were DKK 821 million in the first quarter of 2020 compared to DKK 617 million in the first quarter of 2019. The increase of DKK 204 million, or 33%, was driven by the advancement of epcoritamab (DuoBody
-CD3xCD20) and DuoBody-PD-L1x4-1BB, additional investments in our product pipeline, and the increase in new employees to support the expansion of our product pipeline.. -
Vor oversøiske pandang-aktie er i ATH https://www.google.com/search?q=gmab+nasdaq&oq=gmab+&aqs=chrome.2.69i57j0l2j69i60l2.8636j0j7&client=ms-unknown&sourceid=chrome-mobile&ie=UTF-8
-
IMS U.S. weekly gross sales are down ~15% compared to avg. 4W sales as of end of March and are currently at ~$40 million per week*
-
covid impact
-
MM treatment: Short-term delay, not fundamental disruption
-
Limited visibility into RoW sales
-
Det går som forventet
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind